Subgroup analysis based on age, smoking status, tumor stage, PD-L1 expression level, and whether or not to combine chemotherapy revealed no significant differences in OS between patients in the sintilimab and pembrolizumab groups (Figure 2B). Here, CD274 is linked to neoplasm.